Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH - Kaatz - 2015 -
new oral anticoagulants | PPT
Anthos Therapeutics' Novel Dual-Acting Factor XI/XIa Inhibitor, Abelacimab 150 mg, Demonstrated a 67%
Efficacy and safety of direct oral anticoagulants for secondary prevention of cancer associated thrombosis: a meta-analysis of randomized controlled trials | Scientific Reports
Therapeutic Strategies Following Major, Clinically Relevant Nonmajor, and Nuisance Bleeding in Atrial Fibrillation: Findings From ORBIT‐AF | Journal of the American Heart Association
Evaluation of Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism in the Oncology Population Jessica Hedvat, PharmD PGY-1 Pharmacy. - ppt download
WarfarinApixaban Primary outcome: major/clinically relevant bleeding (through 6 months) Secondary objective: Death, MI, stroke, stent thrombosis Randomize. - ppt download
Clinically relevant non-major bleeding and intra-cranial haemorrhage in... | Download Scientific Diagram
Assessing Bleed Severity and Managing Major and Non-Major Bleeds | Download Scientific Diagram
Direct Oral Anticoagulants: A User's Guide | Consultant360
Practical Management of Anticoagulation in Patients With Atrial Fibrillation | Journal of the American College of Cardiology
Safety outcome of major bleeding or clinically relevant non-major bleeding. | Download Scientific Diagram
Long-Term Risk of Clinically Relevant Non-Major Bleeding During Extended Anticoagulation for Unprovoked Venous Thromboembolism: A Systematic Review and Meta-Analysis - ISTH Congress Abstracts
JCM | Free Full-Text | Effectiveness and Safety of Apixaban vs. Warfarin in Venous Thromboembolism Patients with Obesity and Morbid Obesity
Anticoagulation strategies and clinical outcomes after bleeding events during anticoagulation therapy for venous thromboembolism in the practice-based Japanese registry | Journal of Thrombosis and Thrombolysis
Abstract 12434: Long-Term Clinical Outcomes After Major versus Minor Bleeding in Patients With Atrial Fibrillation: The Fushimi AF Registry | Circulation
Incidence of major and clinically relevant non-major bleeding in patients prescribed rivaroxaban for stroke prevention in non-valvular atrial fibrillation in secondary care: Results from the Rivaroxaban Observational Safety Evaluation (ROSE) study
Management and outcomes of vaginal bleeding and heavy menstrual bleeding in women of reproductive age on direct oral anti-factor Xa inhibitor therapy: a case series - The Lancet Haematology
Cost–utility analysis of apixaban compared with usual care for primary thromboprophylaxis in ambulatory patients with cancer | CMAJ
PACIFIC-AF: Low bleeding rates for asundexian in atrial fibrillation - Medical Conferences
Anthos' Blood Thinner Abelacimab Outperforms Rivals in Safety by 67% in AF Patients
Cancers | Free Full-Text | A Phase II Study to Compare the Safety and Efficacy of Direct Oral Anticoagulants versus Subcutaneous Dalteparin for Cancer-Associated Venous Thromboembolism in Patients with Advanced Upper Gastrointestinal,
Comparison of clinical trial major and clinically relevant nonmajor... | Download Table
Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH - Kaatz - 2015 -
Identification of International Society on Thrombosis and Haemostasis major and clinically relevant non-major bleed events from electronic health records: a novel algorithm to enhance data utilisation from real-world sources | International Journal
